Vaccines for preventing HPV-related anogenital infection and neoplasia.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Human papillomavirus (HPV) is a common sexually transmitted pathogen. Although most anogenital HPV infections resolve within several years, persistent infection may lead to neoplasia of the cervix, vagina, vulva, anus, and penis, and also genital warts. High-risk HPV types 16 and 18 are known to cause approximately 70% of all cervical cancers, and low-risk HPV types 6 and 11 are the main causes of genital warts. Prophylactic HPV vaccines have the potential to block the acquisition of HPV and hence subsequent development of anogenital neoplasia. Results from several clinical trials have demonstrated that the HPV L1 virus-like-particle vaccines are safe and highly immunogenic. These trials have documented a 100% vaccine efficacy in prevention of persistent HPV infection and, more important, of HPV-associated anogenital neoplasia in per-protocol analyses. Widespread vaccination of sexually naïve preadolescent children could substantially reduce the morbidity and mortality associated with anogenital malignancies. Furthermore, such a primary prevention program would also reduce healthcare costs.

Original languageEnglish (US)
JournalThe Journal of the American Osteopathic Association.
Volume106
Issue number3 Suppl 1
StatePublished - Mar 1 2006

Fingerprint

Papillomavirus Vaccines
Condylomata Acuminata
Infection
Papillomavirus Infections
Neoplasms
Papillomaviridae
Virus-Like Particle Vaccines
Human papillomavirus 11
Human papillomavirus 6
Human papillomavirus 18
Vulva
Human papillomavirus 16
Penis
Anal Canal
Vagina
Primary Prevention
Cervix Uteri
Uterine Cervical Neoplasms
Health Care Costs
Vaccination

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vaccines for preventing HPV-related anogenital infection and neoplasia. / Ferris, Daron Gale.

In: The Journal of the American Osteopathic Association., Vol. 106, No. 3 Suppl 1, 01.03.2006.

Research output: Contribution to journalReview article

@article{8aaf4c57fac64fcb976f4a59bd5f56b8,
title = "Vaccines for preventing HPV-related anogenital infection and neoplasia.",
abstract = "Human papillomavirus (HPV) is a common sexually transmitted pathogen. Although most anogenital HPV infections resolve within several years, persistent infection may lead to neoplasia of the cervix, vagina, vulva, anus, and penis, and also genital warts. High-risk HPV types 16 and 18 are known to cause approximately 70{\%} of all cervical cancers, and low-risk HPV types 6 and 11 are the main causes of genital warts. Prophylactic HPV vaccines have the potential to block the acquisition of HPV and hence subsequent development of anogenital neoplasia. Results from several clinical trials have demonstrated that the HPV L1 virus-like-particle vaccines are safe and highly immunogenic. These trials have documented a 100{\%} vaccine efficacy in prevention of persistent HPV infection and, more important, of HPV-associated anogenital neoplasia in per-protocol analyses. Widespread vaccination of sexually na{\"i}ve preadolescent children could substantially reduce the morbidity and mortality associated with anogenital malignancies. Furthermore, such a primary prevention program would also reduce healthcare costs.",
author = "Ferris, {Daron Gale}",
year = "2006",
month = "3",
day = "1",
language = "English (US)",
volume = "106",
journal = "The Journal of the American Osteopathic Association",
issn = "0098-6151",
publisher = "American Osteopathic Association",
number = "3 Suppl 1",

}

TY - JOUR

T1 - Vaccines for preventing HPV-related anogenital infection and neoplasia.

AU - Ferris, Daron Gale

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Human papillomavirus (HPV) is a common sexually transmitted pathogen. Although most anogenital HPV infections resolve within several years, persistent infection may lead to neoplasia of the cervix, vagina, vulva, anus, and penis, and also genital warts. High-risk HPV types 16 and 18 are known to cause approximately 70% of all cervical cancers, and low-risk HPV types 6 and 11 are the main causes of genital warts. Prophylactic HPV vaccines have the potential to block the acquisition of HPV and hence subsequent development of anogenital neoplasia. Results from several clinical trials have demonstrated that the HPV L1 virus-like-particle vaccines are safe and highly immunogenic. These trials have documented a 100% vaccine efficacy in prevention of persistent HPV infection and, more important, of HPV-associated anogenital neoplasia in per-protocol analyses. Widespread vaccination of sexually naïve preadolescent children could substantially reduce the morbidity and mortality associated with anogenital malignancies. Furthermore, such a primary prevention program would also reduce healthcare costs.

AB - Human papillomavirus (HPV) is a common sexually transmitted pathogen. Although most anogenital HPV infections resolve within several years, persistent infection may lead to neoplasia of the cervix, vagina, vulva, anus, and penis, and also genital warts. High-risk HPV types 16 and 18 are known to cause approximately 70% of all cervical cancers, and low-risk HPV types 6 and 11 are the main causes of genital warts. Prophylactic HPV vaccines have the potential to block the acquisition of HPV and hence subsequent development of anogenital neoplasia. Results from several clinical trials have demonstrated that the HPV L1 virus-like-particle vaccines are safe and highly immunogenic. These trials have documented a 100% vaccine efficacy in prevention of persistent HPV infection and, more important, of HPV-associated anogenital neoplasia in per-protocol analyses. Widespread vaccination of sexually naïve preadolescent children could substantially reduce the morbidity and mortality associated with anogenital malignancies. Furthermore, such a primary prevention program would also reduce healthcare costs.

UR - http://www.scopus.com/inward/record.url?scp=33746045349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746045349&partnerID=8YFLogxK

M3 - Review article

VL - 106

JO - The Journal of the American Osteopathic Association

JF - The Journal of the American Osteopathic Association

SN - 0098-6151

IS - 3 Suppl 1

ER -